GoodRx Holdings, Inc.

NasdaqGS:GDRX Stock Report

Market Cap: US$1.0b

GoodRx Holdings Valuation

Is GDRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GDRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: GDRX ($3.12) is trading below our estimate of future cash flow value ($9.75)

Significantly Below Future Cash Flow Value: GDRX is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GDRX?

Key metric: As GDRX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GDRX. This is calculated by dividing GDRX's market cap by their current earnings.
What is GDRX's PE Ratio?
PE Ratio50.4x
EarningsUS$20.56m
Market CapUS$1.04b

Price to Earnings Ratio vs Peers

How does GDRX's PE Ratio compare to its peers?

The above table shows the PE ratio for GDRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average63.1x
HSTM HealthStream
42.4x10.55%US$825.3m
PHR Phreesia
73.3x34.21%US$665.1m
TBRG TruBridge
91.2x62.43%US$388.5m
SLP Simulations Plus
45.5x15.31%US$369.1m
GDRX GoodRx Holdings
51.4x28.66%US$1.0b

Price-To-Earnings vs Peers: GDRX is good value based on its Price-To-Earnings Ratio (51.4x) compared to the peer average (63.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does GDRX's PE Ratio compare vs other companies in the Global Healthcare Services Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
GDRX 50.4xIndustry Avg. 25.8xNo. of Companies13PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GDRX is expensive based on its Price-To-Earnings Ratio (51.4x) compared to the Global Healthcare Services industry average (25.8x).

Price to Earnings Ratio vs Fair Ratio

What is GDRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GDRX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio50.4x
Fair PE Ratio35.7x

Price-To-Earnings vs Fair Ratio: GDRX is expensive based on its Price-To-Earnings Ratio (51.4x) compared to the estimated Fair Price-To-Earnings Ratio (35.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GDRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.06
US$3.18
+3.95%
16.42%US$4.00US$2.25n/a13
Jul ’27US$3.06
US$3.18
+3.95%
16.42%US$4.00US$2.25n/a13
Jun ’27US$3.08
US$3.18
+3.27%
16.42%US$4.00US$2.25n/a13
May ’27US$2.55
US$2.82
+10.41%
17.50%US$3.50US$1.90n/a13
Apr ’27US$2.01
US$2.82
+40.07%
17.50%US$3.50US$1.90n/a13
Mar ’27US$1.87
US$3.16
+69.07%
40.21%US$7.00US$1.90n/a13
Feb ’27US$2.27
US$4.56
+100.91%
28.33%US$7.00US$2.60n/a14
Jan ’27US$2.71
US$4.88
+80.20%
23.56%US$7.00US$3.00n/a15
Dec ’26US$2.74
US$5.09
+85.74%
20.31%US$7.00US$3.00n/a14
Nov ’26US$3.37
US$5.39
+59.81%
19.36%US$7.00US$3.40n/a14
Oct ’26US$5.03
US$5.37
+6.72%
19.51%US$7.00US$3.40n/a14
Sep ’26US$4.35
US$5.37
+23.40%
19.51%US$7.00US$3.40n/a14
Aug ’26US$4.53
US$6.32
+39.44%
21.36%US$9.00US$4.00n/a15
Jul ’26US$4.96
US$6.32
+27.35%
21.36%US$9.00US$4.00US$3.0615
Jun ’26US$3.92
US$6.35
+61.99%
21.02%US$9.00US$4.00US$3.0815
May ’26US$4.64
US$6.56
+41.43%
19.91%US$9.00US$4.75US$2.5516
Apr ’26US$4.43
US$6.69
+50.96%
19.71%US$9.00US$4.75US$2.0116
Mar ’26US$4.98
US$6.71
+34.66%
19.11%US$9.00US$4.75US$1.8717
Feb ’26US$4.77
US$6.88
+44.28%
24.45%US$10.00US$4.25US$2.2717
Jan ’26US$4.65
US$7.15
+53.70%
23.11%US$10.00US$4.50US$2.7117
Dec ’25US$4.84
US$7.34
+51.73%
21.49%US$10.00US$4.50US$2.7416
Nov ’25US$6.19
US$9.47
+53.00%
23.29%US$16.00US$5.00US$3.3717
Oct ’25US$6.93
US$9.56
+37.89%
22.73%US$16.00US$5.00US$5.0318
Sep ’25US$7.90
US$9.56
+20.96%
22.73%US$16.00US$5.00US$4.3518
Aug ’25US$8.75
US$9.60
+9.68%
22.43%US$16.00US$5.00US$4.5318
Jul ’25US$7.82
US$9.51
+21.65%
22.34%US$16.00US$5.00US$4.9619
US$3.18
Fair Value
1.9% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/16 19:32
End of Day Share Price 2026/07/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GoodRx Holdings, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Glen SantangeloBarclays
Allen LutzBofA Global Research
Daniel GrosslightCitigroup Inc